MVA-B
MVA-B, or Modified Vaccinia Ankara B, is an
History
Non-human testing
The vaccine was originally tested on a number of mice and macaque monkeys in 2008 against the Simian immunodeficiency virus (SIV) and it was found to be successful in creating an immune system response to SIV infection.[1][3]
Phase I testing
The initial testing on human subjects was conducted on a testing pool of thirty HIV-free individuals. Six of the pool were given a
The next step with the vaccine within Phase I testing is to conduct a trial with HIV-positive testers, in order to determine if there is a "therapeutical effect of the vaccine" on those already infected with the virus.[1] A randomized controlled trial was published in February of 2015 that involved 30 HIV infected patients, 20 given doses of MVA-B and 10 given a placebo, which showed that the vaccine was capable of increasing T cell response for Gag-specific T cells. This, however, did not improve immune responses in the long run or prevention of resurgence of viral loads after vaccine treatment was concluded.[5] A followup study published in October of 2017 showed that subsequent immunization with the vaccine in HIV positive patients that had received MVA-B four years prior saw a larger immune response and production of binding and neutralizing antibodies to HIV replication.[6]
Virology
In order to create the vaccine, researchers took the prior Modified Vaccinia Ankara virus and added four
See also
- Antiretroviral drug
References
- ^ a b c d e Jesus Diaz (September 28, 2011). "This 90 Percent Successful Vaccine May Be Our Best Chance to Eradicate AIDS". Gizmodo. Retrieved September 29, 2011.
- ^ Stephen Adams (September 29, 2011). "HIV could be 'minor infection' with new vaccine". Irish Independent. Retrieved September 29, 2011.
- ^ a b Gopalan T (September 28, 2011). "Promising Show By HIV Vaccine MVA-B In Clinical Trials". Medindia. Retrieved September 29, 2011.
- ^ Ylva Mossing (September 29, 2011). "Vaccin gör HIV till "mindre infektion"". Aftonbladet (in Swedish). Retrieved September 29, 2011.
- PMID 25724985.
- PMID 29065142.
- PMID 32041218.
Further reading
- Juan García-Arriaza; José Luis Nájera; Carmen E. Gómez; Nolawit Tewabe; Carlos Oscar S. Sorzano; Thierry Calandra; Thierry Roger; Mariano Esteban (August 31, 2011). "A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses". PMID 21909386.
- Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A. López-Fernández; José L. Nájera; Carmen E. Gómez; Felipe García; José M. Gatell; Teresa Gallart; Mariano Esteban (August 2010). "Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS". PMID 20534857.
- Mariano Esteban (December 2009). "Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS" (PDF). Human Vaccines. 5 (12). S2CID 46108898. Archived from the original(PDF) on 2009-12-26. Retrieved September 29, 2011.
- Carmen Elena Gómez; Jose Luis Nájera; Eva Pérez Jiménez; Victoria Jiménez; Ralf Wagner; Marcus Graf; Marie-Joelle Frachette; Peter Liljeström; Giuseppe Pantaleo; Mariano Esteban (April 12, 2007). "Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B". PMID 17113200.
